US FDA On Resuming Normal Manufacturing Operations When Pandemic Recedes
Executive Summary
Focus on restarting production, easing drug shortages and completing quality assurance activities for quarantined batches, agency guidance says.
You may also be interested in...
The Steps Drug Makers Must Take Now To Avoid A Post-COVID-19 Manufacturing Crisis
How pharmaceutical companies should plan to catch up after the pandemic and explain what happened to inspectors.
US FDA issues new guideline on emergency plans
The US Food and Drug Administration has issued final guidance aimed at encouraging manufacturers of so-called "medically necessary drug products" and their raw materials and components to develop contingency production plans for use during emergencies that result in high absenteeism at production facilities.
A Pandemic Template For Swift Approval? Veklury Stability Questions Deferred For Later Study
The US FDA shaved months from review of Gilead’s Veklury (remdesivir) for COVID-19 with post-approval commitments for multiple stability studies. The Pink Sheet takes a deep dive look at discussions within the agency and with the sponsor.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: